Takeda, Moderna partner up to bring 50M coronavirus shots to Japan
Japanese drugmaker Takeda has quickly emerged as one of the leading forces in the fight against COVID-19 as a vaccine manufacturing partner and R&D lead on a convalescent plasma-based therapy. Now, Takeda will help another biotech distribute its potential COVID-19 vaccine in the drugmaker’s home country.
Massachusetts biotech Moderna has tapped Takeda to bring 50 million doses of its mRNA-based COVID-19 shots to Japanese shores as part of a government-backed vaccine distribution effort, the partners said Thursday.
Takeda will import and distribute Moderna’s shot, dubbed mRNA-1273, starting in the first half of next year, as well as handle local regulatory approvals, the drugmaker said. Moderna’s vaccine is currently working through a pivotal, 30,000-patient phase 3 study, with early data expected sometime in late November or after.
Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders
Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!
Financial terms of the deal were not disclosed. A Moderna spokeswoman could not be reached for comment by press time.